China's Cellular Biomedicine Group Announces Reverse Merger

Published: Jan 04, 2013

by Richard Daverman, PhD

January 4, 2013 -- Cellular Biomedicine Group (CBMG), a China-based regenerative medicine company, will conduct a reverse merger with EastBridge Investment Group. EastBridge is a US entity that helps companies (usually from China or other Asia-Pacific countries) go public. CBMG is testing progenitor and dendritic cell therapies as treatments for a wide variety of diseases, including cancer and osteoarthritis. Both of CMBG’s facilities are in China, and its products are aimed at the China market. More details....

Stock Symbol: (OTCQB: EBIG)

Back to news